The Patent Finder

Ratiopharm GmbH

8 patents currently held · Updated Nov 19, 2026
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Aug 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 13, 2027
    The maintenance fee for Co-crystals of ibrutinib with carboxylic acids (US 10,377,758) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
  • 2 fees due Jun 29, 2027
  • 1 fee due Jul 7, 2027
    The maintenance fee for Crystalline form and acetic acid adducts of palbociclib (US 10,526,326) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 21, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,207,112Liquid formulation of G-CSF conjugate
In force
 · USPTO record
In forceUSPTO record
US 8,546,328Liquid Formulation of G-Csf Conjugate
In force
 · Medium confidence
In forceMedium confidence
US 9,403,842Prasugrel in non-crystalline form and pharmaceutical composition thereof
In force
 · USPTO record
In forceUSPTO record
US 9,222,081Method of Producing and Purifying an Active Soluble Sialyltransferase
In force
 · High confidence
In forceHigh confidence
US 9,012,464Novel Salts and Polymorphic Forms of Afatinib
In force
 · High confidence
In forceHigh confidence
US 9,221,815Solid state form of vemurafenib choline salt
In force
 · USPTO record
In forceUSPTO record
US 10,377,758Co-crystals of ibrutinib with carboxylic acids
In force
 · USPTO record
In forceUSPTO record
US 10,526,326Crystalline form and acetic acid adducts of palbociclib
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 8: 10 patents in force now held by others · 57 lapsed for an unpaid fee · 6 ended at full term · 2 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 abandoned · 69 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited